Tradestie Institutional Equity Comparison Engine

SLS vs BOLD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SLS Overall Edge

SLS Captures Institutional Edge (2โ€“0 Pillars ยท 2โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SELLAS Life Sciences Group, Inc. Common Stock (SLS) driven by superior Momentum & Technical, Options & Structure. Fundamentally, SLS trades at N/M Forward P/E with 0.0% operating margin (-82.5% YoY revenue) versus BOLD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SLS sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SLS N/M vs BOLD N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY -82.5% vs +0.0%
Momentum & Technical Winner SLS
1Y +798.7% vs +101.7% ยท 52W Pos 52% vs 62%
Options & Structure Winner SLS
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (N/A IV)
SLS NASDAQ
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$13.66
-8.08% 1D
Market Cap $3.0B
1M Return +20.35%
1Y Return +798.68%
Forward P/E N/M
Unified AI Score
33.6 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 48.9
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
1M Return -4.92%
1Y Return +101.74%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SLS +798.68% BOLD +101.74% Spread: +696.94 pp (SLS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SLS TTM Op. Margin: 0.0% BOLD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLS vs BOLD. Trailing 12-month operating profitability (SLS 0.0% vs BOLD 0.0%) and valuation multiples (SLS N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SLS (2) vs BOLD (4)
Institutional Metric SLS BOLD Criterion Row Winner
Market Capitalization Scale $3.0B $56.2M Larger Scale SLS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -82.5% +0.0% Higher Growth BOLD
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -40.3% -64.6% Higher ROE SLS
52-Week Range Position Momentum 52% ($1โ€“$25) 62% ($1โ€“$3) Stronger Trend BOLD
Beta / 30D Volatility Risk Regime 1.91ฮฒ ยท 550% Vol -0.08ฮฒ ยท 28% Vol Lower Realized Risk BOLD
Unified Institutional Score Composite Signal 33.6 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite BOLD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SLS vs BOLD Buy Guide
SLS CONSOLIDATION
102d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SLS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BOLD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SLS nor BOLD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.